<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="580">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05227118</url>
  </required_header>
  <id_info>
    <org_study_id>8189-017</org_study_id>
    <secondary_id>MK-8189-017</secondary_id>
    <nct_id>NCT05227118</nct_id>
  </id_info>
  <brief_title>MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)</brief_title>
  <official_title>A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of multiple ascending&#xD;
      doses of MK-8189 in participants with Alzheimer's Disease (AD) with or without symptoms of&#xD;
      agitation-aggression and/or psychosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2022</start_date>
  <completion_date type="Anticipated">November 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who experienced an adverse event (AE)</measure>
    <time_frame>Up to approximately 42 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study treatment due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 28 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE will be reported.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>MK-8189</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be assigned to one of the following regimens: Titration 1: 4 mg x 2 tablets Days 1-3; 4 mg x 1 tablet &amp; 12 mg x 1 tablet Days 4-28 OR Titration 2: 4 mg x 2 tablets Days 1-3; 4 mg x 1 tablet &amp; 12 mg x 1 tablet Days 4-6; 12 mg x 2 tablets Days 7-28 OR Titration 3: 4 mg x 1 tablet Days 1-3; 4 mg x 2 tablets Days 4-6; 4 mg x 1 tablet &amp; 12 mg x 1 tablet Days 7-9; 12 mg x 2 tablets Days 10-28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be assigned to one of the following regimens: Titration 1: 2 tablets Days 1-28 OR Titration 2: 2 tablets Days 1-28 OR Titration 3: 1 tablet Days 1-3; 2 tablets Days 4-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8189</intervention_name>
    <description>MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths</description>
    <arm_group_label>MK-8189</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>MK-8189 matching placebo administered orally QD</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        The main inclusion and exclusion criteria include but are not limited to the following:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a documented diagnosis of probable Alzheimer Disease based on National Institute&#xD;
             on Aging-Alzheimer Association criteria for AD, with a history of cognitive and&#xD;
             functional decline with gradual onset and slow progression for at least 1 year before&#xD;
             screening, that is either corroborated by an informant who knows the participant well&#xD;
             or is documented in medical records&#xD;
&#xD;
          -  Lives in the community setting with a reliable trial partner/caregiver or lives alone&#xD;
             in an assisted living facility, with supervision and has a reliable trial&#xD;
             partner/caregiver&#xD;
&#xD;
          -  Has a reliable and competent trial partner/caregiver who must have a close&#xD;
             relationship with the participant and is knowledgeable of the participant's condition&#xD;
             and progress and able to read, understand and speak the designated language at the&#xD;
             study site&#xD;
&#xD;
          -  Can read at the 6th grade level/equivalent as determined by the investigator&#xD;
&#xD;
          -  Has an academic and/or employment history sufficient to exclude intellectual&#xD;
             disability and is able, in the opinion of the investigator, to fully participate in&#xD;
             the study&#xD;
&#xD;
          -  Participants receiving treatment with a cholinesterase inhibitor or other treatment&#xD;
             for AD, must have been on a stable regimen for 3 months prior to screening and there&#xD;
             are no expected changes in co-medication during the study&#xD;
&#xD;
          -  Is able to discontinue any antipsychotic medication they are taking at the time of&#xD;
             Screening&#xD;
&#xD;
          -  Has a body mass index (BMI) &gt; 18 and â‰¤ 35kg/m2, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has agitation/aggression or psychosis that is attributable to concomitant medications,&#xD;
             environmental conditions, substance abuse, or an active medical or psychiatric&#xD;
             condition&#xD;
&#xD;
          -  Has a known history of stroke or evidence from prior magnetic resonance imaging (MRI)&#xD;
             scan (if available) that is clinically important in the investigator's opinion&#xD;
&#xD;
          -  Has evidence of a clinically relevant neurological disorder other than the disease&#xD;
             being studied (i.e., probable AD) at Screening&#xD;
&#xD;
          -  Has a history of seizures or epilepsy within the last 5 years before Screening&#xD;
&#xD;
          -  Has evidence of a clinically relevant or unstable psychiatric disorder&#xD;
&#xD;
          -  Is at imminent risk of self-harm&#xD;
&#xD;
          -  Has a history of alcoholism or drug dependency/abuse within the last 5 years before&#xD;
             Screening&#xD;
&#xD;
          -  Has a history of cancer (malignancy). Exceptions: (1) Adequately treated&#xD;
             non-melanomatous skin carcinoma or carcinoma in situ of the cervix or; (2) Other&#xD;
             malignancies that have been successfully treated with appropriate follow up and&#xD;
             therefore unlikely to recur for the duration of the study&#xD;
&#xD;
          -  Has a family history of long QT syndrome&#xD;
&#xD;
          -  Previously developed severe extrapyramidal symptoms (EPS) following administration of&#xD;
             any prescribed medication or study treatment&#xD;
&#xD;
          -  Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human&#xD;
             immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4&#xD;
             weeks prior to the pre-study (screening) visit&#xD;
&#xD;
          -  Consumes greater than 3 glasses of alcoholic beverages per day&#xD;
&#xD;
          -  Consumes excessive amounts, defined as greater than 6 servings (1 serving is&#xD;
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks,&#xD;
             or other caffeinated beverages per day&#xD;
&#xD;
          -  Is a regular user of cannabis, any illicit drugs or has a history of drug (including&#xD;
             alcohol) abuse within approximately 3 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CITrials ( Site 0007)</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>949-338-9258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Top Medical Research ( Site 0005)</name>
      <address>
        <city>Cutler Bay</city>
        <state>Florida</state>
        <zip>33189</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-971-6883</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Hallandale Beach ( Site 0001)</name>
      <address>
        <city>Hallandale Beach</city>
        <state>Florida</state>
        <zip>33009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>954-455-5859</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Well Pharma Medical Research, Corp. ( Site 0006)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-665-4818</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlanta Center for Medical Research ( Site 0004)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-881-5800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>iResearch Atlanta ( Site 0009)</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>404-537-1281</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008)</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>609-921-3555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates ( Site 0003)</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>908-625-4456</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>January 27, 2022</study_first_submitted>
  <study_first_submitted_qc>January 27, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2022</study_first_posted>
  <last_update_submitted>October 9, 2022</last_update_submitted>
  <last_update_submitted_qc>October 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

